F6T Stock Overview
A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Fate Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.21 |
52 Week High | US$7.59 |
52 Week Low | US$1.85 |
Beta | 1.84 |
11 Month Change | -21.44% |
3 Month Change | -41.98% |
1 Year Change | 0.78% |
33 Year Change | -95.86% |
5 Year Change | -83.13% |
Change since IPO | -56.38% |
Recent News & Updates
Recent updates
Shareholder Returns
F6T | DE Biotechs | DE Market | |
---|---|---|---|
7D | -9.7% | 0.8% | -2.2% |
1Y | 0.8% | -14.4% | 13.3% |
Return vs Industry: F6T exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: F6T underperformed the German Market which returned 13.6% over the past year.
Price Volatility
F6T volatility | |
---|---|
F6T Average Weekly Movement | 9.6% |
Biotechs Industry Average Movement | 6.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: F6T's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: F6T's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 181 | J. Wolchko | www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
Fate Therapeutics, Inc. Fundamentals Summary
F6T fundamental statistics | |
---|---|
Market cap | €254.42m |
Earnings (TTM) | -€161.56m |
Revenue (TTM) | €11.32m |
25.5x
P/S Ratio-1.8x
P/E RatioIs F6T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
F6T income statement (TTM) | |
---|---|
Revenue | US$12.32m |
Cost of Revenue | US$121.93m |
Gross Profit | -US$109.62m |
Other Expenses | US$66.11m |
Earnings | -US$175.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.54 |
Gross Margin | -889.96% |
Net Profit Margin | -1,426.67% |
Debt/Equity Ratio | 0% |
How did F6T perform over the long term?
See historical performance and comparison